Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546840 | 1.00 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL2255636 | 1.00 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL29493294 | 1.00 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL27432132 | 0.90 | NPC1 (0.33) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL17724339 | 0.90 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL17724288 | 0.90 | ALOX15 (0.34) | ALOX15KDM4ENPC1RAB9ACRBN | |
| SCHEMBL29753183 | 0.89 | ALOX15 (0.33) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL20076133 | 0.89 | ALOX15 (0.35) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL21932895 | 0.89 | ALOX15 (0.35) | ALOX15KDM4ENPC1RAB9APTPRC | |
| SCHEMBL2248688 | 0.88 | NPC1 (0.40) | ALOX15KDM4ENPC1RAB9ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725553-A2 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3908582-B1 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12391672-B2 | Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| US-12186311-B2 | Antiproliferative compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4467143-A2 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | Celgene Corporation (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-4461370-A2 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA | Celgene Corporation (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2024-11-07 | — | — | US | disclosed |
| US-20160251333-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION | 2016-09-01 | — | — | US | disclosed |
| US-20160251333-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION | 2016-09-01 | — | — | US | disclosed |
| US-9309220-B2 | Processes for the preparation of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309220-B2 | Processes for the preparation of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309220-B2 | Processes for the preparation of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2882736-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-4-((4-(MORPHOLINOMETHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | Celgene Corporation (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20140046058-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014025978-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-4-((4-(MORPHOLINOMETHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20140046058-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046058-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | CD4, CD2, CD22 | ALOX15 3615/4885KDM4E 521/4885NPC1 3631/4885 |
| US-20160251333-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CYP3A5, CYP1B1, CYP1A2 | ALOX15 1943/4885KDM4E 411/4885NPC1 1519/4885 |
| US-20140046058-A1 | PROCESSES FOR THE PREPARATION OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF | CYP3A5, CYP1B1, CYP1A2 | ALOX15 1943/4885KDM4E 411/4885NPC1 1519/4885 |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | CRBN, LTN1, CBL | ALOX15 2669/4885KDM4E 1016/4885NPC1 4270/4885 |
| US-12186311-B2 | Antiproliferative compounds and second active agents for combined use | NEK4, AURKB, XPO1 | ALOX15 3441/4885KDM4E 402/4885NPC1 2089/4885 |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | ALOX15 3441/4885KDM4E 402/4885NPC1 2089/4885 |
| US-12391672-B2 | Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | FLNB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SF3B2 | ALOX15 3053/4885KDM4E 418/4885NPC1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.